Analysis of Palladia Pharmacokinetics and Pharmacodynamics at Non-Label Dosing
Eligibility Requirements
• Have a sarcoma, carcinoma, melanoma or other solid tumor (excluding histiocytic sarcoma and hemangiosarcoma) that has either failed standard therapy or for which the owner declines standard therapy
• Have a life expectancy of approximately 90 days
• Have completed any chemotherapy or radiation therapy at least 2 weeks prior to enrollment
Study Objective
The goal of this study is to determine the pharmacokinetics (blood levels) of Palladia given to dogs with cancer at doses lower than that recommended on the label.
Compensation
Palladia will be provided at no cost during, and 6 months after the completion of the study representing a savings of $1500-3000 to owners. The owner is responsible for all other costs including office visits and bloodwork. Please click on the link for more details.
Location of Trial
Columbus, Ohio
More information
Canine Mammary Cancer Clinical Trial
Eligibility Requirements
• Dogs can be spayed or intact with diagnosed or suspected multifocal mammary cancer and should have no evidence of tumor spread to the lungs on the basis of chest x-rays although lymph node involvement is acceptable.
• Standard treatment (surgery +/- chemotherapy) is not covered by the trial and ideally will be performed at Auburn University as we will require fresh and sterile biopsy materials to determine diagnosis and to culture tumor cells for follow-up analysis of the patient’s immune response.
• Post-surgical treatment, including all three vaccinations (the treatment protocol lasts approximately 10-12 weeks) followed by three rechecks (during the remainder of one year) will be provided without charge for qualified enrollees.
Study Objective
We anticipate the results of this treatment protocol promise to bring the benefits of molecular and cellular biology to dogs with cancers that would normally severely compromise the quality or end their lives. Through this trial we hope to demonstrate effective treatment of breast/mammary cancer in affected dogs and then to apply this approach to other types of canine cancer as well. The treatment is composed of three vaccinations made from the patient’s own antigen presenting cells (harvested from blood) and a canine mammary tumor-derived cell line in combination with other components designed to enhance immune system recognition. The treatment has proven safe in normal laboratory dogs with few observable side-effects which were low to moderate in severity and resolved quickly without further intervention. We hope our approach provides a more effective management strategy than is currently available to practitioners.
Compensation
This study is partially funded. Please click on link for more details.
Location of Trial
Auburn, Alabama
More information
| 
